Axovant Sciences Ltd (NYSE:AXON) was downgraded by investment analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research report issued on Tuesday, The Fly reports.

A number of other research analysts have also commented on AXON. Robert W. Baird lowered shares of Axovant Sciences from an “outperform” rating to a “neutral” rating in a research note on Tuesday. UBS AG lowered shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Cowen and Company reiterated an “outperform” rating and set a $30.00 price objective on shares of Axovant Sciences in a research report on Wednesday, June 21st. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC started coverage on shares of Axovant Sciences in a research report on Monday, July 10th. They set a “buy” rating and a $40.00 price objective on the stock. Four research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $25.59.

Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12).

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/26/axovant-sciences-ltd-axon-downgraded-to-neutral-at-piper-jaffray-companies.html.

A number of large investors have recently modified their holdings of the business. Lord Abbett & CO. LLC bought a new stake in Axovant Sciences in the second quarter valued at approximately $696,000. California State Teachers Retirement System increased its position in shares of Axovant Sciences by 10.0% during the second quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock worth $1,228,000 after acquiring an additional 4,800 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Axovant Sciences by 16.6% during the second quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock worth $519,000 after acquiring an additional 3,184 shares in the last quarter. State Street Corp increased its position in shares of Axovant Sciences by 52.8% during the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock worth $12,682,000 after acquiring an additional 188,945 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of Axovant Sciences during the second quarter worth $47,854,000.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

The Fly

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.